Literature DB >> 16074500

The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile?

P Dreger, M Ritgen, S Böttcher, N Schmitz, M Kneba.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16074500     DOI： 10.1038/sj.leu.2403800

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

1.  High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.

Authors:  Aaron C Logan; Hong Gao; Chunlin Wang; Bita Sahaf; Carol D Jones; Eleanor L Marshall; Ismael Buño; Randall Armstrong; Andrew Z Fire; Kenneth I Weinberg; Michael Mindrinos; James L Zehnder; Scott D Boyd; Wenzhong Xiao; Ronald W Davis; David B Miklos
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 2.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.

Authors:  Steven Z Pavletic; Shaji Kumar; Mohamad Mohty; Marcos de Lima; James M Foran; Marcelo Pasquini; Mei-Jie Zhang; Sergio Giralt; Michael R Bishop; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-04-24       Impact factor: 5.742

Review 3.  Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome.

Authors:  Maria Chiara Barbanti; Niamh Appleby; Murali Kesavan; Toby Andrew Eyre
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

4.  PCR-based clonality assessment in patients with lymphocytic leukaemias: a single-institution experience.

Authors:  Bojana M Cikota; Ljiljana J Tukić; Olivera T Tarabar; Dragana T Stamatović; Marija N Elez; Zvonko M Magić
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

5.  New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.

Authors:  Lindsay Am Rein; Anthony D Sung; David A Rizzieri
Journal:  Int J Hematol Oncol       Date:  2013-02

6.  Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia.

Authors:  A C Logan; B Zhang; B Narasimhan; V Carlton; J Zheng; M Moorhead; M R Krampf; C D Jones; A N Waqar; M Faham; J L Zehnder; D B Miklos
Journal:  Leukemia       Date:  2013-02-19       Impact factor: 11.528

Review 7.  Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies.

Authors:  Ricardo Sánchez; Rosa Ayala; Joaquín Martínez-López
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.